Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B

Novartis

Overview

This study is being conducted to compare the effectiveness and safety of telbivudine (LdT) and lamivudine in Chinese adults.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Chronic Hepatitis B

Interventions

telbivudineDRUG

lamivudineDRUG

Eligibility

Sex: ALLMin age: 16 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Documented clinical history compatible with chronic hepatitis B infection Other protocol-defined inclusion criteria may apply Exclusion Criteria: * Patient is pregnant or breastfeeding * Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV * Patient has previously received lamivudine or any investigational anti-HBV nucleoside or nucleotide analog Other protocol-defined exclusion criteria may apply

Locations (1)

Unnamed facility

Beijing, China

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.